Lupin credit ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
5,9105,9105,0772,6704,244
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−3,320−3,3208756202,511
0.26×0.26×0.29×0.19×0.34×
−0.15×−0.15×0.05×0.04×0.20×
0.67×0.67×0.96×0.70×2.36×
−0.35×−0.38×0.17×0.16×1.40×
17.12×17.12×13.95×8.39×3.34×
20.8%20.8%22.7%15.7%25.3%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

LUPIN₹1,989.90

Lupin Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMACIPLADRREDDYALKEMFORTISAUROPHARMALAURUSLABSMANKINDMcap ₹90,978 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt4,244.12,669.95,076.75,910.25,910.2
Net Debt2,511.2620.4875.2-3,319.8-3,319.8
Total Debt/Equity0.340.190.290.260.26
Net Debt/Equity0.200.040.05-0.15-0.15
Total Debt/EBITDA2.360.700.960.670.67
Net Debt/EBITDA1.400.160.17-0.38-0.35
Interest Coverage (EBIT/Interest)3.348.3913.9517.1217.12
Total Debt/Total Capital %25.2815.6722.6920.7920.79
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.